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Characterization of nucleocapsid-RNA interactions in Rift Valley fever virus infection
Chairperson: J. Stephen Lodmell
Abstract Content
Rift Valley fever virus (RVFV) is a mosquito-borne virus that infects humans and
livestock and exhibits potential for global spread. No vaccine or treatment is currently
available for human use. The nucleocapsid protein (N) in RVFV is a multifunctional
RNA-binding protein that is necessary for viral replication and dissemination. Because of
its essential roles, N is a promising candidate to be targeted for anti-RVFV therapy. The
goal of this dissertation is to characterize N-RNA interactions in RVFV infected cells. To
achieve this goal, two methods, strand-specific reverse transcription and quantitative PCR
(RT-qPCR) as well as multiple reaction monitoring mass spectrometry (MRM-MS) for
N, were developed. Using strand-specific RT-qPCR, we were able to discriminate
expression levels of viral genomic, antigenomic, and protein coding mRNAs. We
determined that the relative expression levels of viral protein-coding RNAs increased
according to previously published viral promoter strength determinations. However,
expression levels of antigenomic RNAs were independent of the RVFV promoter
strength. Moreover, the presence of NSs protein, the virulence factor for RVFV,
positively correlated with increased viral RNA (vRNA) synthesis. Combining RT-qPCR
and MRM-MS methods with crosslinking immunoprecipitation and RNA sequencing
(CLIP-seq), it was found that N interacts not only with viral but with host RNAs during
infection. The interactions between N and vRNAs increased with infection time, which
correlated with an increase in the specific infectivity of virus particles produced later in
infection. The results provided in this dissertation add important knowledge pertaining to
vRNA synthesis, encapsidation, and packaging in RVFV infection and will be useful in
the development of N-targeting anti-RVFV therapeutics in the future.
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Chapter 1: Introduction
This dissertation focuses on the protein-RNA interactions observed during Rift
Valley fever virus (RVFV) infection in mammalian cells. In this chapter, basic molecular
biology of RVFV as well as key features of the nucleocapsid protein (N), the protein of
interest, are reviewed, and the significance and focus of this dissertation are highlighted.
Information specific to topics discussed in subsequent chapters can be found in the
introduction sections in each chapter.

Rift Valley fever virus
Rift Valley fever virus (RVFV) is a mosquito-borne, RNA virus that belongs to
the order Bunyavirales, family Phenuiviridae, and genus Phlebovirus. The virus is
prevalent in sub-Saharan Africa and the Arabian Peninsula. RVFV infects livestock,
causing symptoms ranging from hepatitis, hemorrhage, abortion, and death1,2. The high
mortality rate in young animals, as well as the high abortion rate, presents significant
damages to local economies3. Transmission of the virus to humans occur through
mosquitoes and by contact with infected animals4. Symptoms of RVFV infection in
human vary widely from mild illness, vision loss to hemorrhagic fever and death. In
addition, studies have shown that RVFV infection can be abortive in mice5 and likely in
humans6,7. No approved vaccine or treatment is currently available for human use.
RVFV has a tripartite, single-stranded RNA genome, designated as the small (S),
medium (M), and large (L) segment that codes for several structural and nonstructural
proteins2. The S segment uses an ambisense coding strategy and encodes nucleocapsid
protein (N) in antigenomic sense and nonstructural protein S (NSs) in genomic sense
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orientation. NSs is the major virulence factor in RVFV that antagonizes the host
interferon response8,9, downregulates host transcription10,11, and degrades the doublestranded RNA-dependent protein kinase (PKR)12,13. The M and L segment are negative
sense and encode polyprotein precursor (ppM) and RNA-dependent RNA polymerase
(RdRp), respectively. ppM can be cleaved into nonstructural protein M (NSm) and
glycoproteins N and C (Gn and Gc). NSm suppresses virus-induced apoptosis14, and the
glycoproteins interact with viral ribonucleoproteins (RNPs) and genomes to package into
nascent virions15-17. The virus also uses an alternative start codon to translate P78 protein
from the M segment. P78 plays a role in viral dissemination in mosquito cells18, and the
overexpression of the protein attenuates the virus in human macrophages19. All viral
mRNAs are transcribed from genomic segments by RdRp except for the NSs-coding
transcript that is transcribed from the antigenomic S segment. These mRNAs have 5’methyl guanosine caps due to the cap snatching activity of RdRp20 but lack poly(A) tails
at the 3’-end21,22. All genomic segments form intramolecular panhandle structure, where
5’- and 3’-end of the genome anneal to each other due to their complementarity, which is
similar to other single-stranded, negative-sense RNA viruses23,24.

Nucleocapsid protein
The nucleocapsid protein (N) of RVFV has been a center of focus in our research
group. N is a multifunctional RNA-binding protein that is necessary for viral
transcription, replication, and packaging2,25. The protein is 27 kDa and consists mostly of
alpha-helices26. N adopts two conformations, open and closed (Figure 1-1). In a model
we described previously, N changes conformation from closed to open upon encountering
RNA27. The shift in conformation exposes the positively charged RNA-binding cleft to
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allow the N-RNA interactions28,29. The N-terminus helical arm interacts with adjacent N
for subsequent cooperative binding and oligomerization along the RNA target28,29.
Because it is important at many stages during viral replication, interfering with N
functions is an ideal antiviral strategy.
Nucleocapsid proteins of other RNA viruses, such as alphaviruses30 and human
immunodeficiency virus type 131, are known to target a sequence or structure motif that is
unique to the viral RNA. A previously conducted SELEX experiment showed that RVFV
N binds to GU-rich sequences32. However, the crystal structure of RVFV N shows a
positively charged RNA-binding cleft without specific base interactions28. The structure
of N-RNA complex was solved by co-crystalizing N and the biologically irrelevant
homopolymer poly(U)28. Therefore, potentially specific N-RNA interactions may have
been overlooked. The specificity of the N-RNA interactions in RVFV remains to be
investigated.

A

B

C

Figure 1-1: Structure of RVFV N
Structure of N protein without RNA (A; closed conformation) and with RNA (B; open conformation).
(C) Electrostatic interactions observed in the RNA-binding pocket of N. PDB: 4V9E, 3LFY, and
4H5O.

Significance and focus of this dissertation
The goal of the research reported in this dissertation was to characterize the NRNA interactions in RVFV infection to further understand the contribution of N in viral
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pathogenesis. The importance of the interactions between the viral RNAs and Gn33, Gn
and RdRp16, as well as N and Gn/Gc34 in the generation of viral particles has been
investigated previously. However, consequences of the N-RNA interactions in terms of
viral genome packaging, remains to be elucidated. Understanding the roles of N in viral
pathogenesis will highlight potential biochemical interactions that could be targeted by
antivirals. In this dissertation, two approaches, a strand-specific reverse transcription and
quantitative PCR (RT-qPCR), as well as multiple reaction monitoring mass spectrometry
(MRM-MS), are discussed as tools to characterize viral RNA and N protein content in
RVFV infected cells. Combining these techniques with cross-linking,
immunoprecipitation and sequencing (CLIP-seq) of RNAs complexed with N protein, the
interactions between N and host/viral RNAs were characterized. The investigation
revealed that the efficiency of viral RNA-N complex formation increases with infection
time. Early in infection, when the concentration of N protein is actively increasing, N
mainly interacts with host RNAs, resulting in production of low-infectivity virions. Later
in infection, when it reaches equilibrium concentration, N readily binds viral RNAs,
forming more infectious viral particles. These results provide sensitive methods for
quantitative analysis of N protein and viral RNAs and add new insights into RVFV
pathogenesis in the context of viral particle production.
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Chapter 2: Characterization of Rift Valley fever viral RNA
synthesis using strand-specific reverse transcription and
quantitative PCR
This chapter focuses on the reverse transcription and quantitative PCR method
that enables quantitation of Rift Valley fever viral RNAs. The method is also described in
our manuscript published in Viruses (https://doi.org/10.3390/v13122417). In addition,
this chapter includes results and discussion on the effect of NSs protein (the virulence
factor in Rift Valley fever virus) in viral RNA synthesis, which were not included in the
manuscript.

Abstract
Quantitation of highly structured RNAs, such as viral RNAs, poses unique
challenges and tends to be laborious as well as costly. To overcome these issues, a strandspecific reverse transcription and quantitative PCR (RT-qPCR) method was developed
and optimized for accurate quantitation of Rift Valley fever viral RNAs. The method can
distinguish genomic, antigenomic, and protein-coding mRNAs. Using this method, copy
numbers of viral RNAs in RVFV infected cells were quantitated. The amount of
intracellular viral RNA molecules linearly increased between 12 and 36 hours post
infection. The expression of viral protein-coding transcripts, but not the synthesis of fulllength genomic/antigenomic RNA, followed previously documented promoter strength
assessments on each segment. Namely, the large segment, which was described to
possess the strongest promoter among three genomic segments, produced the highest
quantity of the protein-coding transcript and a modest amount of its genomic and
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replication intermediate RNA. In addition, to investigate if the NSs protein influenced
viral RNA synthesis, the expression of viral genomic RNAs was quantitated in cells
infected with RVFV with and without NSs. In Vero cells, the suppression of host general
transcription and translation caused by NSs was sufficient to increase viral genomic RNA
synthesis. Taken together, the results suggest segment-dependency in viral RNA
accumulation as well as a potential contribution of NSs in viral genomic RNA synthesis.

Introduction
Rift Valley fever virus (RVFV) produces 10 different RNA molecules during its
replication2. Three of these are genomic RNAs, another three make up antigenomic
RNAs (full-length and complementary copies of genomic RNAs), and four are proteincoding transcripts. The viral polymerase (RdRp) synthesizes both full-length
genomic/antigenomic RNAs (as a replicase) and protein-coding transcripts (as a
transcriptase). RdRp switches its activity between replicase and transcriptase functions,
though the specific mechanism is unknown.
The viral genomic RNAs are called S, M, and L ascribed to the small, medium,
and large segment. Similarly, antigenomic RNAs are designated as agS, agM, and agL.
Viral protein-coding transcripts (N, NSs, ppM, and RdRp) are named after the protein to
be translated from the RNA. All viral protein-coding transcripts, except for the NSs
transcript, utilize genomic RNA as template (Figure 2-1). The NSs transcript, having the
same orientation as the genomic RNA, is synthesized using the antigenomic RNA as
template. These viral RNA (vRNA) molecules are essential for successful viral
replication.
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ppM

RdRp

N

L

M

S

agL

agM

agS
NSs

Figure 2-1: RVFV transcription and replication
Protein-coding transcripts, RdRp, ppM, and N (the top row) are transcribed from genomic L, M, and S
segments. The antigenomic RNAs are full-length complementary copies of genomic segments, and the
NSs protein-coding transcript is transcribed from the antigenomic segment (the bottom row). The viral
protein-coding RNAs are capped (shown as a half circle on the 5’-end). The viral sense RNAs are
shown in darker colors, and the antisense RNAs are shown in lighter colors.

RVFV and host protein-coding RNAs differ in their anatomy. For example, host
protein-coding transcripts, known as messenger RNA (mRNA), possesses a 5’-methyl
guanosine cap and 3’-poly(A) tail. A phleboviral protein-coding transcript carries the 5’cap as a result of cap snatching during its synthesis20, but lacks a poly(A) tail at the 3’end21,22. Accordingly, viral protein translation does not require binding of poly(A)binding protein (PABP), which is utilized by the virus to limit host protein synthesis
during infection35. The 3’-ends of each viral protein-coding transcript have been
characterized and include short untranslated regions (UTRs)36,37. Notably, the 3’-end of
viral protein-coding RNAs are shorter than the corresponding antigenomic RNAs (and
the genomic RNA for the NSs transcript; Figure 2-1)36,37. To distinguish viral genomic,
antigenomic, and protein-coding RNA molecules in the RT-qPCR method described in
this chapter, the difference in 3’-end position is exploited.
The nonstructural protein S (NSs) is the major virulence factor in RVFV
infection. NSs antagonizes the host immune response by downregulating the type-I
interferon expression at the transcription level8,9,11 and by degrading double-stranded
7

RNA-activated protein kinase (PKR)12,13. NSs is also capable of downregulating the host
general transcription by sequestration and degradation of transcription factor II H
(TFIIH) subunits p44 and p6210,38-40. TFIIH plays important roles in RNA polymerase IIdependent transcription41. Therefore, RVFV infected cells show global shutdown of host
mRNA synthesis. Furthermore, NSs can selectively interfere with the translation of host
proteins by retaining mRNAs and translocating PABP to the nucleus35,42. These NSs
functions are summarized in Figure 2-6A.
Quantitating highly structured RNAs, such as vRNAs, is challenging. A typically
used method, like Northern blot, is only semi-quantitative and poses difficulty separating
RNAs that are similar in size. A recently developed fluorescence in situ hybridizationbased method is robust, though it requires an advanced microscope facility and the
saturation of intracellular fluorescence signal later in infection impaired accurate
quantitation43. In this chapter, reverse transcription and quantitative PCR (RT-qPCR)
based method was used to characterize Rift Valley fever vRNA accumulation. In
HEK293 cells, RVFV showed robust vRNA synthesis with highly variable agS and N
transcript expression and more stable agM and M expression. In agreement with
previously published RVFV promoter strength measurements, robust expression of RdRp
and N protein-coding RNAs was observed. Moreover, in Vero cells, the suppression of
host general transcription and translation caused by NSs was sufficient to increase viral
genomic RNA synthesis. In summary, Rift Valley fever vRNA accumulation rate differs
between segments, and the presence of the virulence factor, NSs, potentially enhances the
vRNA synthesis.
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Materials and methods
Cells and viruses
HEK293 and Vero cells were cultured in Dulbecco’s Modified Eagle Medium
(DMEM; Gibco) supplemented with 10% fetal bovine serum (FBS; Gibco) and 1x
penicillin-streptomycin (Gibco) and maintained at 37°C and 5% CO2. RVFV (strain MP12) working stocks were prepared by infecting Vero cells and harvesting supernatant.
Small aliquots of the virus were stored frozen at -80°C until use. The parental stock of the
virus was kindly provided by Dr. Brian Gowen (Utah State University, Logan, UT). The
viral titer was determined by flow cytometry and TCID50.
To infect cells, virus diluted in 2% FBS DMEM was placed on cells and
incubated for 2 hours at 37°C and 5% CO2. Cells were washed, and the medium was
replaced with fresh 2% FBS DMEM. Cells were incubated at 37°C and 5% CO2 for times
indicated in each experiment.

Flow cytometry
RVFV MP-12-infected cells were collected at 8-hour post infection, washed twice
with phosphate buffered saline (PBS), and fixed with 4% formaldehyde in PBS. Fixed
cells were incubated in Permeabilization Buffer (1% w/v bovine serum albumin (BSA),
0.1% w/v saponin, and 0.005% w/v sodium azide in PBS) for 10 minutes at room
temperature and were spun down for 5 minutes at 500g. The permeabilization step was
repeated twice. Then, cells were incubated with anti-N antibody (BEI Resources,
Manassas VA, NR-43188) diluted 1:2000 in Permeabilization Buffer for an hour at room
temperature. After pelleting by centrifugation, cells were washed twice with
Permeabilization Buffer. Alexa 488-conjugated secondary antibody (Invitrogen,
9

Frederick MD, A11001) was diluted 1:2000 in Permeabilization Buffer, and cells were
incubated with the antibody solution for 30 minutes at room temperature. Cells were
washed twice with PBS for 10 minutes at room temperature.
Flow cytometry data were acquired by using Attune NxT Flow Cytometer
(Invitrogen). FlowJo software (Becton, Dickinson & Company) was used for analysis,
and the gating strategy was as follows: side scatter area and forward scatter area define
cells, forward scatter width and forward scatter height define single cells. Infected cells
are defined as single cells that exhibited greater fluorescent signal compared to mockinfected cells when forward scatter area is plotted against BL1 channel signal.

Purification of RNA from cell culture
Cells were lysed by directly adding TRIzol reagent (Invitrogen) to a culture dish,
and RNAs in the aqueous phase was purified by using RNA Clean and Concentrator Kit
(Zymo Research). 50 ng of purified total RNA was used in 5 μL reverse transcription
reaction.

Primer design
The strand specificity in RT-qPCR assay described in this chapter comes from the
reverse transcription (RT) step, where the target specific region of each RT primer
anneals to a sequence specific to the target (Figure 2-2A). The constant region added to
the 5’-end of RT primer carries the universal reverse primer44 binding site and TaqMan
probe binding site. Using the universal reverse primer and probe reduces the cost of
assay, which is ideal for a segmented virus that produces various RNAs. A sequence for
the target specific region of each RT primer was chosen based on the transcription end-
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sites described previously36,37 (Figure 2-2B). Forward primers for qPCR reactions were
designed so that qPCR amplicons are approximately 50 to 150 base-pairs in length and to
match the melting temperature of the universal reverse primer. The TaqMan hydrolysis
probe had 5’-FAM (fluorescein) and 3’-BHQ (blackhole quencher). Moreover, to keep it
short with the optimal melting temperature, a few locked nucleic acids were incorporated
into the probe45,46 (Table 2-2). The primer sequences are summarized in Table 2-1 and 22.

11

A

Constant region

Target specific region

5' GTGCAGGGTCCGAGGT GCTA ACCGCAGAGCCA AC NNNNN...........NNNNN 3'
Reverse primer binding site

B

Probe binding site

L segment
RdRp

L

agL
M

M segment
agM

ppM

S segment
S

NSs
agS

N

Figure 2-2: Primer design for strand-specific RT-qPCR
(A) The design of the reverse transcription (RT) primer used in this method. The constant region was
designed based on the sequence used by Chen et al.44 (B) The regions targeted by each primer. The
blank boxes indicate coding regions for each segment, the black arrows indicate RT primer, and the
white arrows indicate forward primers for qPCR. Note that the drawings are not scaled to one another.
Table 2-1: Primers used to prepare RT-qPCR standards
Target sequences were amplified from pTVT7-GS, -GM, and -GL plasmid by using the primers listed
below. The bolded letters indicate the sequence recognized by T7 polymerase. L = genomic L
segment, agL = antigenomic L segment, RdRp = RNA-dependent RNA polymerase, M = genomic M
segment, agM = antigenomic M segment, ppM = polyprotein M, S = genomic S segment, agS =
antigenomic S segment, NSs = nonstructural protein S, N = nucleocapsid protein.
Target
L
L
agL
agL
RdRp
M
M
agM
agM
ppM
S
S
NSs
agS
agS
N

Name
T7-L_F
L_R
T7-agL_F
agL_R
RdRp_R
T7-M_F
M_R
T7-agM_F
agM_R
ppM_T7_R
T7-S_F
S_R
NSs_R
T7-agS_F
agS_R
N_R

Sequence
TAATACGACTCACTATAGGGGGCAGCTGAATAGTTGACTTGTGG
ACACAAAGGCGCCCAATCA
TAATACGACTCACTATAGGGGGATGCATTCATTCAGGATGCAAG
ACACAAAGACCGCCCAATATTG
CCACATGGATTCCAATACTAGC
TAATACGACTCACTATAGGGTGCTGAGTTGGCCATCACAC
ACACAAAGACGGTGCATTAAATGT
TAATACGACTCACTATAGGGGCCTTAGGGCACCAAACCT
ACACAAAGACCGGTGCAACT
TGCAAAGGGCACAACCTCAT
TAATACGACTCACTATAGGGACACAAAGACCCCCTAGTGC
ACACAAAGCTCCCTAGAGATACAA
GGCAGCCTTAACCTCTAATCAACC
TAATACGACTCACTATAGGGACACAAAGCTCCCTAGAGATACAA
ACACAAAGACCCCCTAGTGC
CTAATCCCGACCGTAACCCC

12

Note
Used with T7-agL_F
Used with T7-agM_F
Used with T7-S_F
Used with T7-agS_F

Table 2-2: Primers and probe used for strand-specific RT-qPCR
Bolded letters indicate the constant region on the RT primer. [+C] indicates locked nucleic acid base.
The abbreviations used in the ‘Target’ column is the same as what’s been used in Table 2-1.
Target
L
L
agL
agL
RdRp
RdRp
M
M
agM
agM
ppM
ppM
S
S
agS
agS
N
N
NSs
NSs
-

Name
L_RT
L_F
agL_RT
agL_F
RdRp_RT
RdRPp_F
M_RT
M_F
agM_RT
agM_F
ppM_RT
ppM_F
S_RT
S_F
agS_RT
agS_F
N_RT
N_F
NSs_RT
NSs_F
RVFV_probe
Universal_R

Sequence
GTGCAGGGTCCGAGGTGCTATCCGCAGAGCCAACGCTAACTCTGGCACTTCCAAC
GAGCCTATTTCAGATGCTCCTTGT
GTGCAGGGTCCGAGGTGCTATCCGCAGAGCCAACACACAAAGACCGCCCAATATTGT
GACCAGTAAGCAAAGTCAGGC
GTGCAGGGTCCGAGGTGCTATCCGCAGAGCCAACTCCGCCACATCTGTCTCC
CGGTGCTCCAGCAAAGACTA
GTGCAGGGTCCGAGGTGCTATCCGCAGAGCCAACGGTGACTCCACTAACCCAGAG
GAGGTCTTAACCTCTCTTATGCCTG
GTGCAGGGTCCGAGGTGCTATCCGCAGAGCCAACACACAAAGACCGGTGCAACT
GCAGCAGTCTCAAGTGCTTG
GTGCAGGGTCCGAGGTGCTATCCGCAGAGCCAACAGTGGAGTCACCAAAGCAGG
TCGGTTCTGGTGTGTGAAGC
GTGCAGGGTCCGAGGTGCTATCCGCAGAGCCAACCTTGCGATCCAGTTTGCTGC
AAGCAAACTCTCGGACCCAC
GTGCAGGGTCCGAGGTGCTATCCGCAGAGCCAACAGGTTGCTCACGTACAGTGC
CAGCATCAGGCTCTCCTCC
GTGCAGGGTCCGAGGTGCTATCCGCAGAGCCAACAACTCTACGGGCATCAAACC
ATCAAGAGCTTGCGATCCAG
GTGCAGGGTCCGAGGTGCTATCCGCAGAGCCAACCACAACAGGGCCCAACCATA
CAGAGTGGTCGTCGTGTTGT
FAM-TGG[+C]T[+C]TG[+C]GGA-BHQ1
GTGCAGGGTCCGAGGT

Synthesis of RNA standards
Single-stranded DNAs were synthesized by Integrated DNA Technologies (IDT;
Coralville AI), and the TaqMan probe was synthesized by Sigma. First, standard RNAs
were in vitro transcribed from double-stranded PCR fragments (Table 2-1) possessing T7
promoter and viral sense, antisense, and transcript sequence. Transcription reactions were
carried out by using TranscriptAid T7 High Yield Transcription Kit (Thermo Scientific),
and products were gel purified. The concentration of each standard was calculated based
on 260 nm absorbance measured by Nanodrop 2000 (Thermo Scientific) and the
theoretical extinction coefficient calculated by OligoAnalyzer Tool (IDT).

Strand-specific RT-qPCR
To generate RT-qPCR standard curves, 0.5 μL of diluted RNA standard was
mixed with 0.5 mM dNTPs, 100 nM reverse transcription primer, 5 mM DTT, 1x
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SuperScript IV Buffer, and 50 units of SuperScript IV (Invitrogen). RT reaction was
carried out for 10 minutes at 50°C, then was terminated by heating samples 10 minutes at
80°C. 20 μL qPCR reactions were assembled with TaqMan Gene Expression Master Mix
(Applied Biosystems), 0.5 μM each forward and reverse primer, 50 nM RVFV probe, and
2 μL RT reaction. The qPCR reactions were carried out by StepOne Real-Time PCR
System (Applied Biosystems), and cycle conditions used are following: 2 minutes at
50°C, 10 minutes at 95°C, then 40 cycles of 15 seconds at 95°C and 1 minutes at 60°C.
All qPCR reactions were performed in duplicate. StepOne Software (v2.3, Applied
Biosystems) was used for data analysis.

End-point PCR
RT reaction was carried out as described above, and 1 μL cDNA was used in 10
μL PCR reaction with Phusion Flash High-Fidelity PCR Master Mix (Thermo Scientific).
PCR cycle conditions used are following: initial denaturation for 10 seconds at 98°C,
then 35 cycles of 1 second at 98°C, 5 seconds at 60°C, and 15 seconds at 72°C. Products
were analyzed on non-denaturing acrylamide gel with tris-borate-EDTA buffer.

Results
Appending the constant region to reverse transcription primers eliminates primerindependent cDNA products
Primer-independent complemental DNAs (cDNAs) are byproducts that are
produced during reverse transcription (RT) reaction47-49. Theoretically, a reverse
transcriptase uses single-stranded DNA primer provided in the reaction to synthesize
cDNAs. However, depending on a sequence and/or structure of the target, the enzyme
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can initiate the RT reaction without the primer, resulting in the production of primerindependent cDNA. The accumulation of primer-independent cDNA is problematic as it
would lead to overestimation of target RNAs in the subsequent qPCR reaction. To
overcome this issue, several groups implemented methods, such as utilizing a
biotinylated RT primer49 and appending an additional sequence to RT primer to be
targeted in the qPCR step48,50. While both methods are robust, the purification of
biotinylated cDNAs is laborious, and using a unique set of reverse primer and probe for
each target could be costly. Thus, the method described here uses RT primers with the
constant region shared among all RT primers, which includes the universal reverse
primer and probe binding site (Figure 2-2A). The method bypasses complicated cDNA
purification and reduces number of primers to be screened for the assay optimization.
To assess if the addition of the constant region eliminated quantification of
primer-independent cDNA during PCR, RT-PCR experiment was conducted by using
two different primer sets: one with the reverse primer that anneals to the constant region
(primer set B) and the other anneals to the target sequence (primer set A; Figure 2-3A).
The primer set A produced PCR bands even when the RT primer was not added to the RT
reaction, indicating that these primers amplified primer-independent cDNAs (Figure 23B). The primer set B produced PCR bands only in the presence of the RT primer. Thus,
appending the constant region to the RT primer eliminated the detection of primerindependent cDNA.
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Figure 2-3: Appending the constant region eliminates the primer-independent cDNA synthesis
(A) The experimental set up. Target viral RNAs were purified from RVFV MP-12 infected HEK293
cells. After RT reaction, the end-point PCR experiment was conducted by using two different primer
sets. Both forward and reverse primers in Primer set A anneals to the viral RNA sequence, whereas
the reverse primer in Primer set B anneals to the constant region of the RT primer (shown as a broken
line). Primer set B is used in RT-qPCR experiments described in this chapter. (B) Products of the endpoint PCR reactions are visualized on non-denaturing acrylamide gels. Primer set A produced signal
in absence of RT primer. Primer set B signal arises only when the strand-specific RT primer is added
to the reaction. Plasmids carrying viral sequences were used as a control for the PCR reaction.

The strand-specific RT-qPCR method is sensitive and demonstrates robust quantification
range
The absolute quantification of viral RNAs in this method requires generation of
standard curves for each target. To mimic the viral RNA molecules, RNA fragments of
approximately 1,000 to 1,700 bases, encompassing the region targeted by RT-qPCR
primers, were transcribed in vitro and purified. The purified RNAs were diluted and
subjected to the RT-qPCR assay to create standard curves. The assay target shows 4- to
7-logs of linear range for all targets, satisfactory correlation coefficient, and qPCR
efficiency (Figure 2-4). The limit of quantification for each viral RNA is also robust with
the lowest being 5 molecules for RdRp RNA. The least sensitive is the assay for the
genomic S segment, showing 5 ´ 104 RNA molecules as the quantitation limit. In
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summary, the strand-specific RT-qPCR method is suitable for quantitation of viral RNAs
and demonstrates robust sensitivity and quantification range.
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Figure 2-4: RT-qPCR standard curves and statistics
(A-J) Standard curves generated from dilutions of in vitro transcribed viral RNAs. The x-axis
indicates log(number of RNA molecules), and y-axis indicates the qPCR threshold count (Ct). Mean
and standard error of mean (SEM) of qPCR duplicates are plotted. (K) Slope, y-intercept, correlation
coefficient (R2), and qPCR efficiency of each primer set.
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Expression of the antigenomic S segment and N protein-coding transcript is highly
variable early in infection
To characterize viral transcription and replication, HEK293 cells were infected
with RVFV (strain MP-12) at multiplicity of infection (MOI) of 0.1. Intracellular RNAs
were then purified at various timepoints and subjected to RT-qPCR. As expected,
numbers of viral RNA molecules increased with infection time (Figure 2-5A-C). Notably,
the expression of a few viral RNAs, namely RdRp and N, seemed to reach a plateau
concentration, while others kept increasing. The expression of S and agS were
surprisingly low compared to other genomic and antigenomic segments. By analyzing
variabilities between two biological samples that were obtained from cells with different
passage numbers, it was found that the expression of agS and N were highly variable
compared to S and NSs RNAs early in infection (Figure 2-5D). On the other hand,
variabilities among the L and M segment RNAs were similar at 12 and 24 hpi. At 36 hpi,
overall reduced variability was observed compared to earlier timepoints, which was
especially striking with agM. Taken together, RVFV vRNAs accumulates over the
infection time with variabilities in the expression levels of agS and N early in infection.
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Figure 2-5: Quantitation of viral RNAs in HEK293 cells
(A-C) Total RNAs purified from HEK293 cells infected with RVFV (strain MP-12; MOI = 0.1) were
subjected to RT-qPCR analysis. Mean and SEM of n = 2 replicates at passage numbers of 2 and 6
(each included biological duplicates) are graphed. (D) Sample variability (the reciprocal of signal-tonoise) of the data represented in (A).
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Host general transcriptional shutdown results in increased viral genomic RNA
production
The NSs protein in RVFV downregulates host general transcription10,11,38,39,
which may alter the nucleic acid metabolism in RVFV infected cells and affect viral
RNA synthesis. Thus, it was hypothesized that the presence of NSs would affect viral
RNA expression in RVFV infected cells. To test this hypothesis, HEK293 cells were
infected with two different strains of RVFV, MP-12 and rLuc, at MOI of 1. MP-12 is the
attenuated strain of RVFV that carries all 7 viral proteins that are common to the wild
type strain, except for several point mutations that cause the attenuation51,52. rLuc, on the
other hand, lacks the open reading frame (ORF) for the NSs protein53. Instead, rLuc
carries enzymatically active Renilla luciferase in the position of NSs ORF53.
Unexpectedly, the NSs-null rLuc strain produced more viral genomic RNAs than MP-12
(Figure 2-6B). It is important to note that to achieve the same MOI, rLuc requires more
viral particles than MP-1233, which likely corresponds to higher viral RNA input in rLuc
infected cells compared to MP-12 infected cells. The greater amount of intracellular viral
RNAs observed in rLuc infected HEK293 cells is likely due to the higher initial viral
RNA load delivered by the rLuc virus. To further elucidate the effect of NSs in viral
replication, Vero cells were infected with MP-12 and rLuc, and the accumulation of
intracellular viral RNAs was quantitated. A few factors related to the antiviral response
are different between Vero and HEK293 cells (Figure 2-6A). Vero cells lack the ability to
produce type I interferons54,55. Thus, the interferon-induced upregulation of PKR is not
expected in Vero cells, though the protein is constitutively expressed at low level56. On
the other hand, HEK293 cells express type I interferons and PKR at detectable levels.
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Using Vero cells enables investigation of possible effects of NSs on vRNA synthesis,
specifically in the context of the downregulation of host general transcription and PABPdependent translation (Figure 2-6A). Unlike in HEK293 cells and even with the initial
disadvantage of low vRNA load, MP-12 was able to produce as many viral genomic
RNAs as rLuc in Vero cells (Figure 2-6C). These results show that general host
transcription shutdown and/or downregulation of PABP-dependent translation caused by
NSs correlate with increased viral genomic RNA synthesis.
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Figure 2-6: Functions of NSs and quantitation of viral RNAs in HEK293 and Vero cells
(A) Expected NSs functions in HEK293 and Vero cells. IFN = interferon, SAP30 = histone
deacetylase complex subunit SAP30 (Sin3-associated polypeptide), p44 = general transcription factor
IIH (TFIIH) subunit 2, p62 = TFIIH subunit 1, PKR = double-stranded RNA-activated protein kinase,
eIF2-alpha = eukaryotic initiation factor 2 alpha, PABP = poly(A)-binding protein. (B and C) Strandspecific RT-qPCR quantitation of intracellular viral genomic RNAs (L, M, and S) in HEK293 cells
(B) and Vero cells (C). Mean and SEM of biological duplicates are shown. Asterisks indicate
statistical significance with p-value = 0.0580 (*), p-values between 0.05 and 0.005 (**), and p-value <
0.005 (***) determined by unpaired t-test.

Discussion
A strand-specific RT-qPCR method described in this chapter is sensitive and can
accurately quantitate viral RNAs obtained from infected cells. Although the assay is
designed to use the TaqMan chemistry, it could easily be adapted to use the SYBR green
chemistry if needed. Moreover, the sensitivity of the method allows to quantitate viral
RNAs from diluted samples, such as a cell culture supernatant. By changing the target
specific region of the RT primer, the assay can also be adjusted for uses with other
pathogens. The strand-specific RT-qPCR described here is a versatile method that can be
used not only for RVFV RNAs but with RNAs from other organisms.
Using the newly developed method, the accumulation of intracellular viral RNAs
was quantitated at three timepoints during RVFV infection (Figure 2-5). As expected, all
viral RNA species showed increase in number of molecules up to 36 hpi. Moreover, the
expression of agS and N protein-coding transcript was found to be more variable between
samples (Figure 2-5D). Both agS and N transcript are synthesized from the genomic S
segment as a template (Figure 2-1). In Bunyamwera virus (BUNV, orthobunyavirus) and
Uukneiemi (UUKV, phlebovirus), a sequence and/or structure element in the UTR region
determines the strength of promoter, resuting in different efficiency of viral RNA
synthesis57-59. For example, BUNV promoter is strongest with the M segment and
weakest with the S segment, which results in the relative RNA abundance of M > L > S58.
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A previous study with RVFV, however, suggested that the L segment promoter is the
strongest, and the M segment promoter is the weakest, which is different from BUNV
and UUKV. The RT-qPCR analysis presented here shows the relative antigenomic RNA
abundance of M > L > S (Figure 2-5A-C), similar to that of BUNV and UUKV.
Interestingly, when only viral protein-coding transcripts are considered, the relative
abundance follows the order of L > S > M (Figure 2-5A-C), consistent with previously
characterized RVFV promoter strength60. It is plausible that RVFV promoters have more
pronounced effect on viral transcription than replication.
The NSs protein in RVFV is a major virulence factor that interferes with the host
immune response, general transcription, and translation61. Because NSs changes the host
RNA metabolism during infection, it was hypothesized that the host general transcription
shutdown caused by NSs aids viral genomic RNA synthesis. By using the strand-specific
RT-qPCR, viral RNAs obtained from MP-12 or rLuc infected HEK293 and Vero cells
were quantitated (Figure 2-6B and C). rLuc requires more viral particles to achieve a
given MOI compared to MP-1233, which is reflected in the consistently higher
intracellular viral RNA content observed in rLuc infected cells (Figure 2-6B and C). With
the downregulation of host general transcription and PABP-dependent translation, MP-12
was able to synthesize as many vRNAs as rLuc in Vero cells (Figure 2-6C). In the
interferon response-competent cells, such as HEK293, the initial viral (and viral genomic
RNA) load appears to be important for efficient viral genome synthesis even in the
presence of NSs. Although it is technically challenging, normalizing the initial viral load
in terms of viral genomic copies might be beneficial in further understanding the
relationships between NSs functions and its effects in viral genomic RNA synthesis.
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Chapter 3: Development of a multiple reaction monitoring
mass spectrometry (MRM-MS) method to accurately quantify
nucleocapsid protein in Rift Valley fever virus infection
This chapter focuses on a quantitative mass spectrometry method developed for
Rift Valley fever virus nucleocapsid protein. The method is used to answer scientific
questions in Chapter 4. In this chapter, rationales for sample preparation and analysis are
highlighted to ease the interpretation of data in the subsequent chapter. The method is
published as a part of our manuscript in Viruses (https://doi.org/10.3390/v13122417).

Abstract
Multiple reaction monitoring mass spectrometry (MRM-MS) is an analytical
method that is used to precisely quantitate a molecule of interest, even in a complex
mixture. The technique is used for characterization of small molecules as well as
macromolecules like proteins. An MRM-MS-based method was developed for the
quantitative analysis of Rift Valley fever virus (RVFV) nucleocapsid protein (N) within
infected cells. The technique enables antibody-independent quantitation of the protein,
unlike other biochemical methods to characterize a protein concentration in a complex
mixture. Moreover, a stable isotope-labeled internal control was used during sample
preparation, which allowed internal calibration of absolute quantities of the protein of
interest. The method exhibits a limit of detection down to 10-femtomole range. The
MRM-MS protocol described in this chapter is an accurate, sensitive, and versatile,
antibody-independent alternative for characterizing the expression of RVFV N.
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Introduction
The nucleocapsid protein (N) in Rift Valley fever virus (RVFV) is a
multifunctional RNA-binding protein2. Common methods to analyze N expression in
cells include Western blotting and immunofluorescence microscopy. These methods are
semiquantitative, and the limit of detection heavily relies on the quality of an antibody
being used. To enable accurate and absolute quantification, a multiple reaction
monitoring mass spectrometry (MRM-MS)-based method was developed for RVFV N.
MRM-MS is typically done on a tandem mass spectrometer coupled with a liquid
chromatography (LC)62. First, a sample is injected to the LC system for separation. Then,
eluting molecules are analyzed by MS1 for an intact (precursor) ion. The precursor ion
that matches the expected mass-to-charge (m/z) of the target molecule is further
fragmented and analyzed by MS2. The fragmentation results in generation of product
ions that are unique to the target molecule. This m/z changes (transitions) between MS1
and MS2 verifies the presence of the molecule of interest in the sample. Moreover, the
monitored ion counts for a transition is used to quantitate the molecule of interest in the
sample. With macromolecules, like proteins, a peptide that originates from the protein of
interest is quantitated, instead of a whole protein. A precursor ion (peptide) produces band y-ions (ions that include the N- and C-terminus of the peptide, respectively) when
fragmented. The sequence specific transition is used to quantitate the peptide amount,
which correlates with the abundance of whole protein in a given sample. With an LCMS/MS method that allows elution of ions in well-separated windows, many transitions
can be measured in one analysis63,64. Thus, MRM-MS can be higher throughput than
existing protein quantitation methods62.
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In this chapter, an MRM-MS technique to accurately quantify RVFV N in cellular
lysate is discussed. This antibody-independent method exhibits a limit of detection at 10femtomole and can be used with common mass spectrometers, such as triple quadrupole
(QQQ) and quadrupole-ion trap (Q-trap) mass spectrometers. The method is applied to
characterize N protein production during RVFV infection in Chapter 4.

Materials and methods
Cells and viruses
Culturing method for HEK293 cells and RVFV (strain MP-12) stock preparation
are described in Chapter 2.

Preparation of 15N-Labeled N
Recombinant N protein was expressed in BL21(DE3) pLysS cells (Promega) by
first preculturing cells in the LB broth containing 50 μg/mL ampicillin overnight at 37°C.
The preculture was pelleted and resuspended in 6 mL M9 medium (per one liter, 60 g
divalent sodium phosphate, 30 g monovalent potassium phosphate, 5g NaCl)
supplemented with Trace Elements (50 μg/mL EDTA, 8.3 μg/mL ferric chloride
hexahydrate, 0.84 μg/mL zinc (II) chloride, 0.13 μg/mL copper (II) chloride dihydrate,
0.10 μg/mL cobalt (II) chloride hexahydrate, 0.10 μg/mL boric acid, and 0.016 μg/mL
manganese (II) chloride hexahydrate), 1 mM MgSO4, 0.3 mM CaCl2, 1 μg/mL thiamin, 1
μg/mL biotin, and 1 mg/mL 15NH4Cl. Then, 1 mL cells were added to 500 mL M9
medium containing 50 μg/mL ampicillin and incubated at 37°C until OD600 reached 0.5.
Next, IPTG was added to 5 mM, and the culture was incubated for 16 hours at 23°C.
Cells were pelleted by centrifugation at 5,000 RPM, 4°C for 20 minutes in F9-6x1000
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LEX rotor (Thermo Scientific) and resuspended in 50 mL E.coli Lysis Buffer (50 mM
Tris-HCK pH8, 300 mM NaCl, 5% Glycerol, 5 mM imidazole, 23 ng/mL PMSF, 21
ng/mL TLCK, 21 ng/mL TPCK, 3.3 ng/mL leupeptin, and 3.3 ng/mL lima bean). 20 mg
lysozyme was added to cells, and after 20 minutes incubation at 4°C, cells were lysed
with a cell disruptor. The lysate was centrifuged for 45 minutes at 36,000 RPM, 4°C in
Ti45 rotor (Beckman, Indianapolis IN), and filtered through a 0.45 μm membrane.
The following purification steps were conducted at 4°C. 15N-labeled N was bound
to Profinity Ni-IMAC resin (Biorad) by running the lysate through a gravity-flow
column. The resin was washed with Wash Buffer (50 mM Tris-HCl pH 8, 500 mM NaCl,
10% glycerol, and 10 mM imidazole), and the protein was eluted with 10 mL Elution
Buffer (50 mM Tris-Hcl pH 8, 500 mM NaCl, 10% glycerol, 300 mM imidazole, and the
protease inhibitors as listed in E. coli Lysis Buffer). The eluate was concentrated down by
centrifugation in Amicon 10 kDa MWCO column (Sigma). Aliquots of purified proteins
were frozen with liquid nitrogen and were stored at -80°C.

Preparation of unlabeled, recombinant N
The unlabeled, recombinant N protein was expressed using the method described
above for 15N-labeled N, but with the LB medium instead of M9 medium. The
purification of the unlabeled protein followed the method used for 15N-labeled protein.

LC-MS/MS analysis of intact N
Recombinant N proteins expressed in E. coli copurifies with bacterial RNAs26. To
avoid potential chromatographical interference by contaminating RNAs, N was first
denatured in Urea Buffer (50 mM ammonium bicarbonate and 8 M urea) for 1 hour on
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ice. Then, the protein was buffer exchanged into buffer containing 20% acetonitrile and
50 mM ammonium bicarbonate by centrifugation in Amicon 10 kDa MWCO filter unit
(Sigma). Approximately 5 μg of N was injected into Agilent 6520 Quadrupole-Time of
Flight mass spectrometer coupled to Agilent 1260 UPLC (Agilent, Santa Clara CA). The
protein was separated through AdvanceBio RP-mAb C4 Column (3.5 μm, 2.1 x 75 mm;
Agilent) with a linear LC gradient of 80% Solvent A (0.1% formic acid in water) and
20% Solvent B (0.1% formic acid in acetonitrile) to 50% Solvent A and 50% Solvent B
over 10 minutes with 0.500 mL/minutes flow rate. The column was heated to 50°C
during analysis. On the mass spectrometer, gas temperature was set to 325°C, gas flow
was set to 8 L/minutes, Vcap was set to 4500 V, and fragmentor was set to180 V.

Sample preparation for MRM-MS
HEK293 cells were infected with RVFV MP-12. Cells were washed twice with
PBS, scraped off the plate, transferred to a tube, and pelleted by centrifugation for 10
minutes at 1,000g. Cell pellets were resuspended in PBS and lysed with Urea Lysis
Buffer (50 mM Tris-HCl pH 8.3, 75 mM NaCl, and 8 M urea). Lysates were briefly
sonicated to reduce viscosity and spun down for 20 minutes at 10,000g. The total protein
content was estimated by using Bradford assay. 0.1 μg 15N-labeled N was added per 30
μg total protein. Samples were reduced with DTT, denatured in NuPAGE LDS Loading
Buffer (Invitrogen) by heating 10 minutes at 70°C, and fractionated on SDS-containing
acrylamide gel. To avoid distortion, less than 50 μg samples were loaded per lane of a
minigel. Fractionated proteins were stained with Coomassie, and a band corresponding to
N was excised, minced, and transferred to a clean tube. The gel pieces were destained
twice for 20 minutes at 37°C, by incubating in Destaining Buffer (50 mM ammonium
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bicarbonate and 50% (v/v) acetonitrile). Next, the gel pieces were incubated for 10
minutes at 55°C in Reducing Buffer (50 mM ammonium bicarbonate and 50 mM DTT)
and for 1 hour at room temperature in Alkylation Buffer (50 mM ammonium bicarbonate
and 14 mM iodoacetamide). The gel pieces were washed twice in Destaining Buffer for
15 minutes at 37°C and dehydrated in acetonitrile. Then, acetonitrile was removed, and
all samples were air dried. MS-grade trypsin (Pierce) containing Digestion Buffer (50
mM ammonium bicarbonate and 1 mM CaCl2) was added to the gel pieces to rehydrate.
Extra Digestion Buffer was added to cover gel pieces, and samples were incubated
overnight at 37°C. Peptide-containing supernatant was transferred to a clean tube and
desalted by using Peptide Desalting Spin Column (Pierce). The eluate was dried in
SpeedVac, and the pellet was stored at -80°C until analysis.

MRM-MS for RVFV N
Initial screening for peptides ideal for MRM-MS was performed using an Agilent
6520 Quadrupole-Time of Flight mass spectrometer coupled to Agilent 1260 UPLC
(Agilent). Native or 15N-labeled recombinant N protein was digested with trypsin and
peptides were separated using AdvanceBio Peptide Mapping column (2.7 μm, 120 Å, 2.1
x 100 mm; Agilent) over 90 minutes with a gradient of 3-50% Solvent B (acetonitrile
with 0.1% formic acid) and Solvent A (water with 0.1% formic acid). Peptides were
identified using Morpheus software with a precursor mass tolerance of 1.2 Da, product
mass tolerance of 0.5 Da, and maximum FDR of 1%. For MRM, an Agilent 6460 Triple
Quadrupole mass spectrometer in-lined with Agilent 1200 binary LC system was used for
analysis. The peptide mapping column was used for the separation of peptides. The LC
gradient used is as follows: increase Solvent B from 5% to 30% over 2 minutes, increase
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Solvent B from 30% to 40% over 5 minutes, increase Solvent B from 40% to 85% over
one minute, hold at 85% Solvent B for 3 minutes, and re-equilibrate back to 5% Solvent
B over 3 minutes. The flow rate was set at 0.3 mL/minute, and the column was kept at
50°C. The injection volume was 5.00 μL. To avoid carryovers, blank injections were
performed between different samples. On the mass spectrometer, the gas temperature was
set at 325°C, sheath gas flow was set at 11 L/minute, and capillary voltage was set at
4000 V. For MRM, the y9 ion of the P164-178 peptide (AILDAHSLYLLQFSR) were
monitored. The transition of endogenous N monitored was Q1 = 874.1 m/z to Q3 =
1126.4 m/z, with fragmenter = 180 V and collision energy = 45 V. The transition of 15Nlabeled N monitored was Q1 = 884.6 m/z to Q3 = 1139.6 m/z, with fragmenter = 180 V
and collision energy = 43 V. Dwell for all transitions were set at 100. MRM area under
the curve (AUC) was calculated by using Mass Hunter software (Agilent). To estimate
the absolute amount of endogenous N in the sample, the ratio of the amount spiked-in to
AUC for 15N-labeled N was calculated. Then, AUC obtained from endogenous N was
multiplied by the ratio calculated from 15N-labeled N.

Results
Preparation of 15N-labeled N
Stable isotope labeling is a method commonly used to create internal standards for
mass spectrometry assays62. In the MRM-MS method described in this chapter, 15Nlabeled, recombinant N protein acts as a control for both sample preparation and analysis.
The MRM-MS method is designed to go through steps during sample preparation to
reduce sample complexity and maximize detection of a target peptide (Figure 3-1).
However, each sample is expected to exhibit different trypsin-digestion efficiency during
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preparation, which would lead to inconsistent MS signals. Therefore, using a labeled,
whole protein (as opposed to using a stable isotope-labeled peptide) that acts
biochemically identical to endogenous, unlabeled N is an ideal strategy to account for any
sample loss and differences in digestion and purification efficiency.
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Figure 3-1: Design for MRM-MS sample preparation and analysis
RVFV infected cells are lysed, and 15N-labeled N protein is added to the lysate as an internal control.
To reduce complexity of the sample, the lysate is fractionated on a denaturing acrylamide gel. The
region corresponding to the size of N (27 kDa) is excised, and the protein is in-gel digested. The
digested protein is desalted and analyzed on the triple quadrupole mass spectrometer, monitoring the
Q1 (MS1) to Q3 (MS2) transition of the representative peptide.

The 15N-labeled N was expressed in E. coli and purified as explained in the
materials and methods section. 1 L of E. coli culture resulted in approximately 15 mg of
purified protein. The purity of the protein was assessed by denaturing gel electrophoresis
and LC-MS/MS (Figure 3-2). 6x-histidine/asparagine (HN)-tagged N proteins (both with
and without 15N labeling) showed expected masses. The larger mass deviation (-3.3 Da
from theoretical average mass) observed with 15N-labeled N is likely because of the of
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NH4Cl (99% 15N) used for the protein expression (Figure 3-2B). Surprisingly, the LC-

MS/MS analysis also showed peaks that are 178 Da heavier than the expected masses.
The addition of 178 Da corresponds to the gluconoylation on the HN-tag65. Because a
removal of HN-tag resulted in precipitation of the protein, and the modified tag should
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not affect subsequent MS analysis, the gluconoylated N was used as the internal standard
and for method optimization.

A

Lysate

IMAC

+ESI Scan (rt: 9.159-9.631 min, 58 scans) Frag=180.0V N.d
+ESI Scan (rt: 9.295-9.659 min, 45 scans) Frag=180.0V N15.d

B

Unlabeled

1

WC Ins Sol FT Res x Elu
kDa
Counts (x102)

30023.2

75
48
25

0.5

29845.0

0
-0.5

11

15

N

30224.7
30403.1

29000

30000
31000
Deconvoluted mass (amu)

Figure 3-2: Analysis of purified N protein
(A) 15N-labeled N was expressed in E. coli and purified by nickel immobilized metal affinity
chromatography (IMAC). WC = whole cell, Ins = insoluble fraction, Sol = soluble fraction, FT =
flow-through, Res = resin, x = empty lane, and Elu = IMAC eluate. (B) Accurate mass analysis of
unlabeled and 15N-labeled N. The expected average mass is 29844.0 amu for unlabeled N and 30228.0
amu for 15N-labeled N.

Initial screening to find a peptide suitable for MRM-MS
The MRM-MS method quantifies a protein of interest by estimating the
abundance of one or few peptide(s) representing the protein. An ideal, representative
peptide is unique to the protein, does not include easily modifiable amino acids, and
ionizes well during MS analysis62. In silico digestion of N primary sequence by Skyline
(https://skyline.ms/project/home/begin.view; last accessed November 30, 2021) resulted
in several peptide candidates suitable for MRM. To identify ionizable peptide, trypsin
digested N was analyzed on a quadrupole time-of-flight mass spectrometer (Figure 33A). Peptide identity was mapped by Morpheus66, and several peptides were shown to
exhibit Q-value of 0 corresponding to the match with high confidence level (Figure 3-
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3B). Among them, the peptide, spanning amino acids 164-178 (P164-178) with the
sequence, AILDAHSLYLLQFSR, was chosen as the representative peptide for RVFV N.
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Figure 3-3: Analysis of purified N digest
(A) Total ion count spectrum for digested N analyzed over 70 minutes LC gradient. (B) List of
peptides identified with high confidence (Q-value = 0%). The peptide eluting at the retention time (Rt)
= 35.3 minutes was chosen for the subsequent MRM analysis. [C] = carbamidomethylated cysteine.

Detection of P164-178 peptide by MRM-MS
In MRM-MS, identity of the peptide is confirmed by analyzing the m/z transition
of the target peptide between MS1 (Q1) and MS2 (Q3). Skyline software predicted that
the P164-178 peptide produces three y-ions that can be detected by Q3 with m/z of 926.5,
1039.5, and 1126.4. By analyzing digested N protein by a triple quadrupole mass
spectrometer, the 874.0 (Q1) to 1126.4 (Q3) transition was found to produce a robust and
stable signal. Thus, this transition was chosen to be monitored during quantitation of N.
With the transition to be monitored, LC gradient, fragmentor voltage, collision
energy, and dwell time were optimized for both 15N-labeled and unlabeled peptide. The
settings used in the subsequent analysis are described in the materials and methods
section. With the optimized method, the P164-178 peptide eluted around 5.5 minutes,
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producing peaks with AUC that are concentration dependent (Figure 3-4). By serial
dilution of the digested N protein sample, the limit of detection, where the signal-to-noise
ratio was approximately 3, was estimated to be 10 femtomoles. In summary, the P164178 peptide produces robust Q1 and Q3 signals and suitable for quantification of N
protein.
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Figure 3-4: MRM chromatogram for the 874.0 (Q1) to 1126.4 (Q3) transition
2-fold dilution series of digested N protein was analyzed by the optimized MRM-MS method. The
signal shows proportional decrease with concentration of the peptide.

Discussion
Common methods to detect and quantify a protein of interest in a complex
mixture, such as cellular lysate, involves the use of an antibody specific to the protein.
Although these methods are relatively easy, the limit of detection is heavily antibody
dependent. Also, raising and characterizing an antibody against non-cellular protein, such
as viral proteins, can be laborious and costly. The same sample preparation method can
also be adapted for analysis with a quadrupole-ion trap mass spectrometer. The mass
spectrometry-based method discussed in this chapter, MRM-MS, is an antibody
independent, sensitive, versatile, and accurate technique to quantitate the protein of
interest.
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Chapter 4: Time-resolved analysis of N-RNA interactions
during RVFV infection shows qualitative and quantitative
shifts in RNA encapsidation and packaging
This chapter is a modified version of the manuscript published in Viruses
(https://doi.org/10.3390/v13122417).

Abstract
Rift Valley fever virus (RVFV) is a negative sense, tripartite RNA virus that is
endemic to Africa and the Arabian Peninsula. It can cause severe disease and mortality in
humans and domestic livestock and is a concern for its potential to spread more globally.
RVFV’s nucleocapsid protein (N) is an RNA-binding protein that is necessary for viral
transcription, replication, and the production of nascent viral particles. Crosslinking,
immunoprecipitation, and sequencing (CLIP-seq) was conducted to characterize N
interactions with host and viral RNAs during infection. In parallel, multiple reaction
monitoring mass spectrometry (MRM-MS) was used to precisely measure intracellular N
levels. The investigation revealed that N binds mostly to host RNAs at early stages of
infection, yielding nascent virus particles of reduced infectivity. The expression of N
plateaus 10-hours post-infection whereas the intracellular viral RNA concentration
continues to increase. Moreover, the virions produced later in infection had higher
infectivity. Taken together, the detailed examination of these N-RNA interactions
provides insight into how the regulated expression of N and viral RNA produce both
infectious and incomplete, non-infectious particles.
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Introduction
Genome encapsidation and packaging are important processes for virus in
creating infectious particles. Because RVFV harbors a multipartite genome, packaging of
all three genomic segments into a virion is required to form a fully infectious particle.
The mechanism of RVFV genome packaging has been shown by several groups to be
adaptable. For example, the creation of two- and four-segmented versions of RVFV is
possible, suggesting the flexibility of packaging67,68. A codon-shuffled M segment can
also be packaged, implying a weak requirement for an internal packaging signal43. On the
other hand, the 5’-untranslated region (5’-UTR) of the M segment was shown to be
important for packaging of the S and L segments69. Unlike other segmented RNA viruses,
RVFV appears not to form supramolecular RNA complexes consisting of the three
genomic segments during infection43. Moreover, genome packaging efficiency (i.e. the
proportion of virus particles that are fully infectious) depends on cell type; arthropod
cells, such as C6/36, show more efficient packaging than mammalian cells, like
VeroE670. Furthermore, packaging genomic RNAs enhances the release of viral particles,
suggesting the presence of a quality-control or surveillance mechanism16. Genome
packaging in phleboviruses probably involves many host factors as well, and the
complete mechanism remains unknown. Nonetheless, the interactions between the viral
proteins Gn, RdRp, and N with vRNAs are critical within the process8.
Previous studies revealed the importance of the interactions between viral
glycoproteins and RdRp16, N34, and genomic and antigenomic RNAs33 in the context of
virion packaging. Likewise, the encapsidation of RNAs by N is expected to be a
significant event, as enveloped RNAs are largely associated with N26. However, the
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landscape of N-RNA interactions in RVFV infected cells remains unknown. It was
hypothesized that the N concentration qualitatively and quantitatively drives N-RNA
interactions and this dictates which RNAs are packaged into nascent virions. In this
chapter, crosslinking, immunoprecipitation, and sequencing (CLIP-seq) was used to
characterize the interactions between N and RNAs in RVFV (MP-12) infected cells.
During the course of infection, N interacts with vRNAs as well as host protein-coding
and non-coding RNAs, mostly in the cytosol. Somewhat unexpectedly, CLIP-seq, cell
fractionation, and confocal analysis all revealed the presence of N in the nucleus of cells,
where it interacts with various nuclear RNAs. In addition, multiple reaction monitoring
mass spectrometry (MRM-MS; Chapter 3) was used to precisely quantitate N expression
in RVFV infected cells. We found that the intracellular N expression increases
exponentially early in infection and plateaus by 10 to 12 hpi. Additionally, N binds
mostly to host RNAs early in infection, whereas the N-vRNA interactions predominate
later in infection, which correlates with the increased specific infectivity of viral particles
produced at later during infection. Combining the precise measurements of RNAs and N
with the high throughput sequencing data, we show apparent requirements for production
of infectious and incomplete viral particles and suggest a mechanistic advantage for
collective infection, in line with recently proposed sociovirology-based spreading
strategies71.

Materials and methods
Cells and viruses
HEK293 and Vero cells were used in this study. The culturing methods are
described in Chapter 2.
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Flow cytometry
The method is described in Chapter 2.

CLIP-seq lysate preparation
Approximately 107 MP-12-infected HEK293 cells (MOI = 0.1) were collected at
various time points as follows; cells were washed twice with cold PBS, UV crosslinked
for 0.4 J/cm2 then 0.2 J/cm2, scraped, and pelleted. The pellets were flash frozen in liquid
nitrogen and stored at -80°C until use.
Cell pellets were lysed with 350 μL PXL Buffer (0.1% SDS, 0.5% sodium
deoxycholate, 0.5% IGEPAL, and 1x mammalian protease inhibitor cocktail (Gold
Biotechnology, Saint Louis MO) in PBS) by incubating on ice for 10 minutes. 10 μL
DNase RQ1 (Promega, Madison WI) and 3.6 μL diluted RNase T1 (Thermo Scientific; to
final concentration of 1:10,000) were added to each lysate. All tubes were incubated for 5
minutes at 37°C, then digestion was quenched by placing tubes on ice. The lysates were
spun for 20 minutes at 14,000 RPM 4°C, and the clear supernatant was transferred to a
clean tube. 20 μL of the supernatant was kept as Size-Matched control sample and was
stored at -80°C until use. Volume of the remaining lysates were adjusted to 1 mL with
PXL Buffer.

Immunoprecipitation
50 μL of Protein A/G magnetic beads (Pierce, Rockford IL) were prepared with
20 μg of anti-N antibody (Maine Biotechnology Services, Portland ME, MAB240P, lot
1611296.1P) according to the manufacturer’s instructions. 1 mL lysate was added to the
beads and incubated end-over-end at 4°C overnight. The samples were washed twice
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each with LiCl Buffer (250 mM LiCl, 10 mM Tris-HCl pH 8.0, 1 mM EDTA, 0.5%
sodium deoxycholate, and 0.5% IGEPAL), NaCl Buffer (50 mM Tris-HCl pH 7.4, 1M
NaCl, a mM EDTA, 0.1% SDS, 1% IGEPAL, and 0.5% sodium deoxycholate), and KCl
Buffer (50 mM HEPES-KOH pH 7.5, 500 mM KCl, and 0.05% IGEPAL), then once
with Dephosphorylation Buffer (1x Antarctic phosphatase buffer from NEB, Ipswich
MA). Samples were incubated with 5 μL Antarctic phosphatase (NEB) in
Dephosphorylation Buffer for 30 minutes at 37°C, then washed twice each with
Phosphatase Wash buffer (50 mM Tris-HCl pH 7.5, 20 mM EGTA, and 0.5% IGEPAL)
and 1 mL PNK Buffer (-) DTT. End-labeling of RNA was carried out in PNK Buffer (50
mM Tris-HCl pH 7.5, 10 mM MgCl2, and 1 mM DTT) with 2 μL gamma-32P-ATP
(Perkin Elmer, Boston MA) and 5 μL T4 polynucleotide kinase (Thermo Scientific). The
reactions were incubated for 30 minutes at 37°C. Finally, washes were performed once
each with PNK Buffer (-) DTT, LiCl Buffer, NaCl Buffer, and KCl Buffer. The N-RNA
complexes were eluted by adding 50 μL 1x NuPAGE LDS Loading Buffer (Invitrogen)
to the beads.

Size selection of immunoprecipitated N-RNA complexes
The IP samples were denatured 10 minutes at 70°C and fractionated on 10%
acrylamide Bis-Tris gel with NuPAGE MOPS-SDS buffer (Invitrogen). Protein-RNA
complexes were transferred onto a nitrocellulose membrane with NuPAGE transfer
buffer (Invitrogen) for 1 hour, 30 V at room temperature. The region corresponding to NRNA complex was excised. The RNA was eluted from the membrane by digesting the
protein with proteinase K (Sigma, Saint Louis MO) in PK Buffer (4 mg/mL proteinase K,
200 mM Tris-HCl pH 7.5, 100 mM NaCl, 20 mM EDTA, and 2% SDS) for 30 minutes at
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55°C. RNAs were purified by phenol-chloroform extraction followed by ethanol
precipitation. RNA concentration in each sample was determined by Qubit microRNA
assay (Invitrogen). Size-matched samples, stringent CLIP-seq controls recommended by
the ENCODE project (https://www.encodeproject.org/ last accessed November 30, 2021),
were used in this study, which were prepared side-by-side with the IP samples (Figure 41A).

Sequencing library preparation and deep sequencing
CLIP-seq libraries were prepared by using NEBNext Ultra II Directional RNA
library prep kit (NEB). PCR products were fractionated on a non-denaturing acrylamide
gel, and the region corresponding to CLIP-library (200 – 400 base pairs) was excised.
The fragments were eluted in Elution Buffer (500 mM ammonium acetate pH 8.0, 0.1%
SDS, 1 mM EDTA, and 10 mM magnesium acetate) overnight at 37°C. Finally, the DNA
fragments were desalted by using DNA Clean and Concentrator kit (Zymo Research,
Irvine CA). Sequencing reactions were carried out by Illumina HiSeq sequencer
(Novogene, Tianjin, China).

Bioinformatics analysis
All FASTQ files were first analyzed by FastQC (Babraham Bioinformatics), and
the adaptors were trimmed by using Cutadapt72. For the quality control, FastQC was run
again to ensure adaptor removal. Then, reads were mapped to either human genome
(hg38) or RVFV genome (GenBank: DQ375404.1, DQ380208.1, and DQ380154.1) by
using RNA STAR73 with default options for the paired-end sequencing, the strand flag
(XS) output, and without soft-clipping. Mapped reads were indexed, position sorted, then
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deduplicated by using samtools markdup with -r and -s options (http://www.htslib.org/
last accessed November 30, 2021). For peak calling analysis of host RNAs, PEAKachu
(https://github.com/tbischler/PEAKachu last accessed November 30, 2021) was used with
two biological replicate sequencing data and the size matched control data, and with the
default parameters, except for --paird_end and --max_insert_size 150 options. Peaks are
then annotated by using UROPA074 with the default parameters, except for
“strand”:”same” “internals”:”1.0” and “show_attributes”;”all” options. For the analysis of
reads that aligned to MP-12 genome, mapped and deduplicated reads were visualized by
using Integrated Genome Viewer75 (version 2.8.10). FastQC, Cutadapt, RNA STAR, and
PEAKachu were run through the Galaxy server76.

Immunofluorescence and confocal microscopy
Coverslips were prepared in 6-well plates by incubating with poly-D-lysine
(Gibco) for an hour at room temperature. The coated coverslips were then washed three
times with sterile water and dried. HEK293 cells were grown on the coverslip and
infected as described above. On the day of harvest, cells were fixed with 4% (v/v)
formaldehyde in PBS, then permeabilized with 0.1% (v/v) Triton-x100 in PBS. Cells
were blocked by incubating with Blocking Buffer (2% (w/v) BSA in PBS) and were
stained with anti-N antibody (BEI Resources, NR-43188) diluted 1:2000 in Blocking
Buffer overnight at 4°C. Cells were washed three times with Blocking Buffer, and
incubated with Alexa 488-conjugated secondary antibody (Invitrogen, A11001) diluted
1:8000 in Blocking Buffer for 2 hours at room temperature. Slides were washed three
times with PBS, mounted with ProLong Diamond with DAPI (Invitrogen), and cured for
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24 hours at room temperature. Images were obtained by using Zeiss Laser-Scanning
Microscope 880 and analyzed by using Zen Lite (Zeiss, White Plains NY).

Western blot
HEK293 cells were transfected with a FLAG-N expression plasmid by using
Lipofectamine 2000 (Invitrogen). At 24 hpi, cells were harvested by trypsinization and
centrifugation. After two washes with PBS, cells were swollen with Hypotonic Lysis
Buffer (20 mM HEPES pH7.4, 10 mM NaCl, 3 mM MgCl2, and 1x Protease inhibitor
(Gold Biotechnology)) and lysed with 27G needle in presence of 25 μg/mL digitonin.
Digitonin is a mild detergent that has been shown not to lyse nuclei77. Insoluble, nuclear
fraction was pelleted by centrifugation for 10 minutes at 1,500g, washed with PBS, and
lysed with NuPAGE LDS Sample Buffer (Invitrogen). Soluble, cytoplasmic fraction was
spun down for 15 minutes at 10,000g, and the clear supernatant was kept for analysis.
Samples were electrophoresed under reducing and denaturing conditions, and transferred
onto a PVDF membrane overnight. Antibodies used for the blotting were: anti-FLAG
(Sigma, F3165, 1:2000), anti-GAPDH (BioLegend, 607901, 1:1000), anti-histone H2B
(BioLegend, 606301, 1:1000), anti-mouse IgG (Sigma, A2554, 1:6000), and anti-rat IgG
(BioLegend, 405405,1:2000).

Purification of RNAs and strand-specific RT-qPCR
This method is described in Chapter 2.

Multiple reaction monitoring mass spectrometry for RVFV N
This method is described in Chapter 3.
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Results
N binds viral and cellular RNA during infection
N participates in various steps in the viral life cycle. N may regulate transcription
and replication by acting as a chaperone for vRNAs. In addition, interactions with N are
required for RNAs to be packaged in nascent virions. To characterize the N-RNA
interactions in RVFV MP-12 infected cells over the course of infection, crosslinking,
immunoprecipitation, and sequencing (CLIP-seq) was used. RVFV-infected HEK293
cells were UV-irradiated, and the N-RNA complexes were immunoprecipitated (Figure
4-1A). During the library preparation, RNase T1 concentration was optimized to produce
RNA fragments with sizes ideal for the subsequent sequencing reactions. The authentic
N-RNA complex purified from an intact virion, is known to be nuclease registrant26.
Thus, the RNase T1 digestion was performed in presence of several detergents. The
overdigested N-RNA complex showed a distinct band around 41 kDa (Figure 4-1A),
which is in good agreement with the expected supershift of the 27 kDa protein. The 41
kDa band corresponds to an N monomer crosslinked to a small piece of RNA, which
provides a reference for the size exclusion step78. To account for cellular
ribonucleoprotein complexes that non-specifically bind to beads during
immunoprecipitation (IP), the pre-IP, size-matched control79 was prepared side-by-side
with the experimental sequencing libraries. The sequences obtained from the control
library are subtracted from the experimental sequencing results at the time of
bioinformatics analysis. The RNAs purified from the ribonucleoprotein complexes were
subjected to deep sequencing followed by bioinformatics analysis. A total of 125 million
mapped reads were obtained from biological duplicate sequencing libraries and the size-

44

matched control library combined. At 12 hpi, the majority of RNA copurified with N was
cellular RNA (Figure 4-1B). The proportion of reads that aligned to vRNA species
increased as the infection time progressed. At 36 hpi, the vRNA reads exceeded 74% of
total mapped reads. Notably, the raw number of reads that were identified as host RNA
stayed consistent at all time points tested (Figure 4-1C). Therefore, the increase in the
ratio of viral:human RNA copurified with N at later time points was due to increased NvRNA interactions.
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Figure 4-1: CLIP-seq library construction workflow and basic read statistics
(A) CLIP-seq libraries were prepared by crosslinking and immunoprecipitating N-RNA complexes.
The size-matched samples were also prepared as a control by running pre-immunoprecipitation (IP)
lysate on a gel and by purifying RNAs from the corresponding region. (B) CLIP-seq mapping
statistics. N copurified mostly with human RNAs at 12 hpi, while at 36 hpi, more than 74% of
copurified RNAs were viral. (C) Raw number of reads obtained from CLIP-seq libraries. Means and
standard error of means (SEM) of two biological replicates are plotted in the graphs.

N binds host cell protein-coding transcripts
Various host RNAs, including those that are expressed in response to viral
infection, are expected to be present in the cytoplasm. To characterize host RNAs that
copurified with N, peak calling analysis was conducted using PEAKachu
(https://github.com/tbischler/PEAKachu last accessed November 30, 2021), followed by
peak annotation by UROPA74. Early in infection N was observed to bind primarily to
host RNAs without strong clustering at specific loci, although one peak corresponding to
an uncharacterized region of the human genome was found at 12 hpi (Figure 4-2A). At
later time points, however, an increasing number of peaks were identified, namely 271
peaks at 24 hpi and 1794 peaks at 36 hpi. At these timepoints, approximately 50% of total
peaks were associated with unique Ensembl gene IDs (ENSGs). PANTHER gene
ontology analysis (http://geneontology.org/ last accessed November 30, 2021) of these
ENSGs revealed that transcripts for proteins that participate in metabolic processes and
protein biosynthesis (ribosomal proteins and translation initiation/elongation factors)
were enriched at 24 hpi. At 36 hpi, in addition to the processes found at 24 hpi,
chromosome organization (histone proteins), and protein folding (chaperones and
chaperonins) were enriched. Although antiviral protein transcription is upregulated and
therefore transcripts are more abundant during infection, none of the timepoints indicated
with statistical significance that N specifically targeted transcripts coding for antiviral
proteins as a group.
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Published crystal structures of N show a positively charged cavity that can
interact with the negatively charged RNA backbone, suggesting that N, in this
conformation, does not recognize particular RNA sequences26,28,29. However, if N-RNA
interactions were entirely nonspecific, it would be expected for N to bind to RNAs that
are most abundant during infection. To test this, these CLIP-seq peaks were compared to
previously published transcriptome data of RVFV MP-12 infected cells80 (Figure 4-2B
and C). At both 24 and 36 hpi, the majority of peaks found in CLIP-seq did not correlate
with significantly upregulated or downregulated transcripts, although several peaks were
found on transcripts that are upregulated during viral infection, such as the pseudogenes
ANKRD26P1 and RPSAP56 at 24 hpi, and cellular viral response genes IFIT2, IFNB1,
CXCL10, and OAS3 at 36 hpi.
To further characterize the host transcripts bound by N, 24 and 36 hpi peaks were
sorted into transcript biotypes (Figure 4-2D and E). At both timepoints, protein coding
transcripts, which are expected to be less highly structured and therefore more available
for protein interaction, produced the largest number of peaks. A few peaks belong to
RNAs that are known to contain both highly ordered structures as well as some single
stranded regions, such as ribosomal RNAs and transfer RNAs.
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Figure 4-2: Peak calling analysis of reads aligned to human RNAs
To find regions on transcripts to which N was highly bound, peak calling analysis was conducted. (A)
Number of peaks with Ensembl gene ID (ENSG). (B and C) Crossover analysis between CLIP-seq
(this study) and transcriptomics of HEK293 cells infected with MP-12 80. CLIP-seq peaks were
identified on transcripts that are neither up- or down-regulated, with the following exceptions.
ANKRE26P1 and RPSAP56 at 24 hpi (B) and IFIT2, CXCL10, OAS3, IFNB1, RP11-29H23.5,
RPL24P4, and FSCN3 at 36 hpi (C). (D and E) Transcript biotypes of each peaks found at 24 hpi (D)
and 36 hpi (E). NMD = nonsense mediated decay. lncRNA = long noncoding RNA. misc.RNA =
miscellaneous RNA that includes ribosomal RNA and vault RNA. snRNA = small nuclear RNA.
miRNA = micro RNA. snoRNA = small nucleolar RNA. TEC = to be experimentally confirmed ESTs
(expressed sequencing tags). NA = not applicable (no transcript biotype assigned to the peak).
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Notably, some processed transcripts, including transcripts containing a retained
intron(s), small nuclear RNAs (snRNAs), and small nucleolar RNAs (snoRNAs), also
produced peaks, which was unexpected since these RNAs are known to mainly localize
to the nucleus. Since RVFV replicates in the cytoplasm, interactions between N and
nuclear RNAs would require either translocation of N to the nucleus or nuclear RNAs to
the cytoplasm. The N localization was investigated by confocal microscopy and found
that a fraction of N was indeed present in the nucleus as early as 8 hpi (Figure 4-3A).
During infection, RVFV expresses NSs, a nuclear protein that is known to change
localization of a host poly(A)-binding protein35. To test if the presence of N in the
nucleus was a result of altered nuclear permeability caused by NSs, HEK293 cells were
transfected with an N expression vector and were fractionated into nuclear and the
cytoplasmic fractions. N was detected in both cytoplasmic and nuclear fractions in the
absence of NSs, indicating that N itself can translocate into the nucleus (Figure 4-3B).
Taken together, these data demonstrated that N is able to bind to host RNAs both in the
cytoplasm and in the nucleus.

49

A

DAPI

N

Merge

Zoom

Hours post infection

2

4

8

24

B
Transfection
N

-

WC
+

Cyto
- +

Nuc
- +

GAPDH
Histone 2B
Figure 4-3: N localizes to cytoplasm and nucleus after 8-hpi
(A) z-Slice images from confocal microcopy analysis. MP-12-infected HEK293 cells were fixed at
indicated timepoints and stained with anti-N antibody. Scale bars = 10 μm. (B) Western blot. HEK293
cells were transfected with a recombinant FLAG-N expression plasmid and fractionated into the
cytoplasmic (Cyto) and the nuclear (Nuc) fractions. WC = whole cell. GAPDH = cytoplasmic marker.
Histone 2B = nuclear marker.
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N exhibits high- and low-density binding regions on viral sense and antisense RNAs
To characterize vRNAs that were copurified with N, the read coverage on each
sense antisense vRNA was visualized by Integrative Genomics Viewer75 (Figure 4-4A).
A few common features were shared among the three RVFV segments. For example,
there were more pronounced peaks (regions with high read density) and valleys (regions
with low read density) in sense versus antisense RNA. By visual inspection, A-rich and
GU-rich sequences were found in the valley and peak regions, respectively. Although the
number of reads that mapped to a given segment varied greatly, the overall peak/valley
profile was similar across all three timepoints tested. Thus, N exhibits preferential
binding within a sense and antisense segment independent of progress in infection.
The analysis of read coverage across the three different segments showed,
surprisingly, that a greater number of reads were mapped to the antisense segments (note
that the y-axes on Figure 4-4A are scaled to the tallest peak represented). It is important
to note that the relatively short CLIP-seq reads cannot readily distinguish viral proteincoding mRNAs and antigenomic RNAs (and the S genomic segment and the NSs
transcript) unless a read was mapped to the 3’-UTR, which would be present only in
antigenomic RNAs (and the S genomic RNA in case of S versus NSs). Therefore, the L
and M sense RNAs are defined as the genomic L and M segment, respectively. For the S
segment, the sense RNAs are the combined read counts for the genomic S segment and
the NSs protein-coding transcript. The antisense RNAs are defined as the combination of
the antigenomic segments and the protein-coding transcripts (RdRp for L, the polyprotein
for M, and N for S). By normalizing the read counts to the number of nucleotides in each
segment, it was found that N copurified with more antisense RNAs than their counterpart
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sense RNAs in all segments (Figure 4-4B). If antisense RNAs were expressed more
robustly than sense RNAs, N would be expected to bind to these high-concentration RNA
species at higher frequency. To investigate the expression of sense and antisense vRNAs,
each vRNA species was quantitated using strand-specific RT-qPCR (Chapter 2). At all
timepoints tested, approximately twice as much L and S antisense RNAs were present
than their sense RNA counterparts (Figure 4-4C). The M segment was the exception,
where roughly equal amounts of sense and antisense RNAs were observed. Thus, since N
association with M segment RNAs does not mirror their relative abundances, these data
suggest N exhibits higher affinity toward M antisense RNA than M sense RNA.
To understand the dynamics of viral transcription, viral mRNA expression was
estimated by using RT and qPCR primers that target different regions of vRNAs to
specifically differentiate viral mRNAs from other vRNA species (Chapter 2). For the L
and S segment, antisense protein-coding transcripts (RdRp and N) are robustly expressed
throughout infection (Figure 4-4D and F), contributing to the high counts for antisense
molecules represented in Figure 4-4C. The expression of N protein-coding transcript is
especially striking as 10- to 19-fold more N transcript is expressed than the antigenomic
S RNA (Figure 4-4F). In summary, the pattern of N binding to sense and antisense RNAs
was similar through different time points of infection, and N showed a general preference
for the antisense M segment over the sense segment.
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Figure 4-4: CLIP-seq read coverage on RVFV MP-12 sense/antisense segment and quantitation of
intracellular viral RNAs
(A) Read coverages on RVFV RNAs are visualized. From top to bottom, 12, 24, and 36 hpi. The
scales of the y-axes are defined by the height of the tallest peak at each timepoint. ppM = polyprotein
M. (B) Statistics of reads-per-base CLIP-seq coverage. (C-F) Stranded RT-qPCR quantification of
intracellular RNAs harvested from HEK293 cells infected with RVFV (MP-12) at MOI of 0.1. Means
and SEMs of n = 2 biological replicates are plotted. L = L genome. agL = L antigenome. M = M
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genome. agM = M antigenome. S = S genome. agS = S antigenome. RdRp, ppM, N, and NSs signify
coding-transcripts for these proteins.

N concentration increases exponentially early during infection
Previous studies have shown that RVFV (Clone 13) infection can produce
incomplete particles that include only one or two viral genomic segments43. To assess
whether a low concentration of N at the early stages of infection might contribute to
incomplete packaging, multiple reaction monitoring mass spectrometry (MRM-MS;
Chapter 3) was used to quantify N at several timepoints post infection.
At earlier timepoints when cells received an average of one viral particle (MOI =
1), N expression increased 2-fold every two hours up until the plateau observed around
0.3 μg N per mg of total protein (Figure 4-5A). In this system, it typically takes 10 to 12
hours until all cells that were initially infected with virus to reach the threshold level of N
expression that can be detected by flowcytometry. Here, approximately 55% of the cells
were N-positive by 12 hpi (Figure 4-5B). Among the cells that received virus(es), N
expression followed a biphasic pattern of initial exponential increase followed by a linear
phase. At early timepoints and low MOI, the observed exponential increase of N
expression is due to increasing intracellular concentration since the major release of
nascent particles and spreading infection falls outside the 10 hpi time window43.
To characterize N expression under conditions in which cells are collectively
infected, the N protein level was quantitated with cells infected at higher MOI and later
timepoints (Figure 4-5C). Between 12 and 36 hours, all cells are expected to be infected
with multiple virus particles from the inoculum and newly released viruses. Accordingly,
the flow cytometry analysis of the cell populations showed about 90% of cells expressing
N (Figure 4-5C). Even with extended time over 24 hours and with higher MOI, the N
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expression increased exponentially only up to 12 hpi. Because N mRNA concentrations
were shown to remain high at later time points (Figure 4-4F), this could reflect either that
cellular translation was impaired after 10 hpi as a response to viral infection67,81 or that
higher N concentrations promoted autoregulatory translational suppression82. In
summary, N protein expression exponentially increases early in the infection and is kept
at steady state by unknown mechanisms.
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Figure 4-5: Quantitation of N protein expression by MRM-MS
(A and B) Quantitation of N protein expression by MRM-MS (left panels), and the flowcytometry
analysis of N expressing cells in corresponding samples (right panels). HEK293 cells were infected
with MP-12 at MOI = 1 to characterize N levels arising from single infections (A) and later timepoints
with MOI = 2 to observe effect of multiple/collective infection (B). Means and SEMs of n = 2 or 3
biological replicates are plotted.
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Cells produce more infectious virus later during infection
To understand the consequence of N binding to host RNAs at early time points
(Figure 4-1B), the specific infectivity of viral particles with respect to each genomic
segment was characterized. First, HEK293 cells were infected with RVFV, and the
supernatant containing viral particles was harvested at indicated timepoints. The
supernatant was used to extract viral RNA for RT-qPCR, as well as to determine the endpoint titration (median tissue culture infectious dose; TCID50). By taking the ratio of the
end-point titration to vRNA, the number of fully infectious particles per vRNA molecules
(TCID50/vRNA) can be estimated. Growth of RVFV MP-12 on HEK293 cells has
previously been characterized53. In addition to the three viral genomic segments, the
number of antigenomic S (agS) segment was also quantitated since a previous report
showed that the RNA is also packaged33. At 12 hpi, principally the L, M, and agS were
packaged (Figure 4-6). The S segment concentration fell below the quantification limit at
12 hpi, which is consistent with the low intracellular concentration estimated at the same
timepoint (Figure 4-4F). Then, at 36 hpi, the specific infectivity increased by 50- (M
segment) to 260-fold (L segment) compared to those at 12 hpi. The increased specific
infectivity at 36 hpi suggests that a greater proportion fully infectious and fewer
incomplete particles were present in the cell culture media, demonstrating increased
packaging efficiency. Although infected cells are known to release vRNAs in
exosomes83,84, the amount of such vRNAs is relatively minor that does not likely
influence the assay. Therefore, more infectious viral particles were produced later in
infection, which correlates with the N-vRNA interactions observed in RVFV infected
cells (Figure 4-1B).
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Figure 4-6: Specific infectivity of viral particles
(A) HEK293 cells were infected with MP-12 (MOI = 0.1), and the virus-containing cell culture media
were harvested at indicated timepoints. Viral genomic RNA and the antigenomic S segment in media
were quantified using strand-specific RT-qPCR, and TCID50s were measured to determine net
infectious units. To express values in log scale, the ratio of TCID50/vRNA was transformed by
multiplying by 103 (1000 TCID50/vRNA). Means and SEMs of n = 2 biological replicates are plotted.
The star indicates that RNA in the sample was below quantification range. (B) Viral growth curve at
timepoints shown in (A). HEK293 cells were infected with MP-12 at MOI = 0.1. Means and SEMs of
n = 2 biological replicates are shown.

Discussion
In this chapter, the quantitative assessment of N protein and viral RNA levels
along with a complete cataloging of N-RNA interactions were used to address knowledge
gaps in the molecular virology of RVFV infection. In particular, these results elucidate
the extensive interaction network of N with host and viral RNAs, the dynamics of N and
vRNA levels as a predictor of nascent viral infectivity, and suggest that formation of
incomplete virus particles and collective infection of cells is inherent in the overall virus
spread strategy of RVFV.

Consequences of N binding to host RNAs
The CLIP-seq experiment was conducted to characterize the interactions between
N and RNAs during RVFV infection. During the first replication cycle (within 12 hours
of infection with MOI of less than 1), N binds mostly to host RNAs even though robust
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expression of vRNAs is observed (Figure 4-1B and C). Among host RNAs, N associated
largely with protein-coding transcripts, consistent with the notion that N localizes mainly
to the cytoplasm and binds single-stranded RNAs. The investigation revealed, however, a
fraction of N was found in the nucleus and bound nuclear RNAs. Nuclear localization of
N has been observed for some other RNA viruses that replicate in the cytoplasm85,86, but
this has not been observed in the phleboviruses. Because no nuclear localization signal
has been characterized in RVFV N, and the ratio of nuclear/cytoplasmic N was rather low
(Figure 4-3A), N likely enters the nucleus by diffusion through nuclear pores87.
We previously reported that RVFV infection changes the host pre-mRNA splicing
landscape80. Splicing requires direct interactions between the spliceosome and premRNAs and occurs co-transcriptionally within the nucleus88. Therefore, since N binds
abundantly to host RNAs and is localized partially to the nucleus, it is plausible that N
could interfere with the function of splicing machinery by direct competition. The
instances of N binding to intron-containing RNAs were found in the CLIP-seq analysis,
although there is no broad overlap between bound host RNAs and those that were
determined by RNA-seq analysis80 to be differentially spliced during infection. These
results suggest that N does not cause generalized splicing changes through direct,
competitive interactions with host pre-mRNA transcripts, although other interactions with
host splicing machinery cannot be ruled out.
N was found to interact with several transcripts that are upregulated during RVFV
infection, including IFNB1, IFIT2, and OAS3 (Figure 4-2B and C). IFNB1 is a wellstudied cytokine that is released in response to a viral infection89. IFIT2 is expressed in
response to the interferon-alpha/beta signaling and is characterized as an antiviral protein
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in influenza A infection and West Nile Virus90,91. OAS3 expression is also induced
through the interferon signaling pathway, and the protein acts against viral infection92,93.
The interactions with these transcripts and N may be due to the increased concentration
of the host transcripts, or N may target them by recognition of RNA sequence or
structural motifs that have not been characterized. It remains unknown whether the
interactions between N and these antiviral protein-coding transcripts affected the protein
levels, although this would constitute an intriguing strategy to evade host antiviral
responses. It is notable that nucleocapsid proteins of other viruses have been shown to
interfere with the host antiviral response94-97.
Recent studies on packaging of RVFV vRNAs showed that infected cells can
produce empty and incomplete virions43. Specifically, about 40% of Clone13 virions
produced on Vero cells completely lacked viral genomic RNA, and only about 10% of
virions included all three genomic segments necessary for establishing an infection43. As
shown by the creation of two- and four-segmented RVFV and by the rescue of the virus
with the codon-shuffled M segment, the packaging of RVFV vRNA is adaptable and
perhaps stochastic43,67,68. However, the presence of N is necessary for any RNAs to be
packaged to nascent viral particles. Although direct interactions between RVFV
glycoprotein and vRNAs are possible33, it is expected that packaged RNAs are largely
associated with N. Therefore, N interactions with host RNAs at least partially explain the
production of empty and incomplete virions during RVFV infection.
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N binding bias on vRNAs
Based on the cooperative binding model of N and RNA27, it was expected that
vRNAs, especially viral genomic RNAs, would be completely coated by the N oligomer.
The CLIP-seq coverage on vRNAs, however, shows uneven binding density of N to the
vRNA species (Figure 4-4A). Whether N targeted specific sequence or structure motifs
for binding is not yet clear. Moreover, it was surprising to observe higher coverage on
viral antisense RNAs than on viral sense RNAs in all segments (Figure 4-4B). Strikingly,
the RT-qPCR analysis of the M segment (Figure 4-4C) showed that while there was equal
expression of sense and antisense RNAs, the antisense species was more highly occupied
by N, suggesting that the antisense M segment may possess more elements targeted by N
for binding, or for steric reasons, N can more easily oligomerize along the RNA. It is also
plausible that the requirement for intensive transcription of mRNAs from the genomic
segments makes them less amenable to high static occupancy by N. It is also notable that
the high N occupancy of the agM segment corresponds to efficient production of
genomic M segments (Figure 4-4D-F), suggesting that high coverage with N could
contribute to efficient synthesis of the genomic segment, and thereby highlighting
potential mechanistic differences between mRNA transcription and generation of fulllength replication intermediates.

Dynamics of N expression and N-vRNA interactions during RVFV infection
To understand the dynamics of expression, MRM-MS (Chapter 3) was used to
quantitate N protein in RVFV infected cells. The results showed that N expression first
increased exponentially to reach a plateau around 10 hpi (Figure 4-5A). After the first
exponential phase, N expression was increased only modestly even with higher MOI
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(Figure 4-5B). It was previously reported that, as a cellular response to RVFV infection,
translational arrest occurs in the same time window as we observe the leveling of the N
protein expression81,98. Thus, it may be critical for the virus that the rapid increase in
intracellular N concentration occurs before the translational arrest to ensure successful
progression of infection.
In contrast to the intracellular N protein concentration, which stays relatively level
after 10 hpi, vRNA expression steadily increases throughout the infection (Figure 4-4C).
With rising vRNA expression, the N protein switches its preferred binding target from
host RNAs to vRNAs (Figure 4-1B). As reported previously, intracellular abundance and
the balanced expression of vRNAs are important for vRNA packaging70,99. The N-RNA
interactions dictated by the concentration of both species may be a critical determinant
for initiating a productive packaging process. Although the results suggest preferential NvRNA interactions as genome levels rise, the specific sequence or structural motifs
preferred by N and host RNAs remains to be elucidated. The published RVFV N
structures were solved by co-crystalizing non-viral RNAs with N28, thus some
biologically relevant N-RNA interactions that are required during viral replication may
not be represented. It may also be possible that, as shown in Crimean-Congo hemorrhagic
fever virus, N is capable of two binding modes; one is specific for a sequence/structure
motif and the other for non-specific binding100.

Formation and roles of incomplete viral particles
In this chapter, the N-RNA interactions and viral particle production were
characterized as a function of accumulation of vRNA species and N (Figure 4-7). The
quantitation of vRNA contents and fully infectious particles in cell culture media showed
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that the specific infectivity of the virus increases with infection time (Figure 4-6). In
recent years, the formation of non-membrane bound RNA-protein complexes has been
gaining attention as a strategy to efficiently condense vRNA-protein complexes for
packaging101,102. Formation of RNA-protein condensates is tightly controlled by the
concentrations of both RNA and protein species103. For RVFV, the formation of
supramolecular complexes that include all three genomic segments is not a prerequisite to
viral genome packaging43. Though the formation of multi-segment, supramolecular
complexes may not be important in RVFV infection, single-segment condensates may be
used to produce viral particles that carry a subset of vRNA segments.
Viral particles that carry less than the full set of genomic segments are obviously
not fully infectious by themselves. However, they can be useful for subsequent infection
in neighboring cells. For example, assuming they package RdRp and one or more viral
genome segments, incomplete particles could initiate a pre-infection with strategic
expression of viral proteins. Subsequent collective infection with a complete or
complementary virus particle could be more efficient and have a higher chance of
producing more infectious virus. Although the prospect requires further investigation,
(pre-)priming of neighboring cells with critical viral structural or host evasion proteins
could be an attractive strategy for segmented viruses to successfully establish an
infection.
Viral particles can disperse as a single particle or as an aggregated group71. If a
particle containing the L and M segment traveled together with a particle containing the S
segment only, the outcome of the group entering a cell would resemble a full infection
caused by a complete virus. Layers of cells in natural hosts, such as epithelial cell layers
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that are known to be targeted by RVFV104, are in close contact with each other. This
would accentuate the virion aggregation that is a characteristic of cell-to-cell spread71.
Relying on collective infection may be a simple strategy for viruses with a short one-step
replication time43,70.
These results suggest that there is not strong evolutionary selective pressure for
RVFV to have a tightly controlled packaging mechanism, as dispersal of incomplete
particles and collective infection of mammalian cells appears to be sufficient for robust
virus spread between cells. Interestingly, RVFV packaging efficiency is different
between mammalian and mosquito cells70. It would be of interest to precisely
characterize the relationships between the N protein accumulation and the specific
infectivity with multiple strains and in different hosts.
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Figure 4-7: Formation of infectious and non-infectious viral particles
During the middle stage of infection (Mid), when N protein expression is actively increasing, the viral
particles released include more host RNAs than vRNAs, resulting in low specific infectivity. At later
stages of infection (Late), when N protein expression is stabilized and viral RNAs are at their peak
abundance, the viral particles released include more vRNAs and have higher specific infectivity.
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Chapter 5: Conclusions and future directions
RVFV is a human and animal pathogen that poses significant threats to both
human health and local economies. There currently is no vaccine or treatment approved
for human use. Thus, understanding RVFV pathogenesis is desired for advancing
therapeutic capability in viral infection. In this dissertation, the interactions between
RVFV N and RNA, essential to successful viral dissemination, were investigated. This
work presents two newly developed methods to quantitate viral RNA and a viral
structural protein in infected cells. Combining these methods and next-generation, highthrouput sequencing, the interdependency of N-RNA interactions and the specific
infectivity of nascent viral particles has been highlighted. The results shown in this
dissertation provide important insight into the production of Rift Valley fever viral
particles, which can be further extrapolated to better understand the RVFV pathogenesis
in future studies.

Viral RNA synthesis and promoter activity
One significant outcome of the research presented in this dissertation was the
development of a sensitive and accurate method to measure abundance of all ten species
of viral RNA that are produced during RVFV infection. In particular, the method allows
for the discrimination between viral mRNAs and antigenomic RNAs. The RVFV genome
carries 3’- and 5’-UTR on each segment. The UTR regions are thought to include a
sequence or structure motif(s) that drives viral transcription and replication. In Chapter 2,
the viral RNA expression in RVFV infected HEK293 cells was characterized by using
strand-specific RT-qPCR. The results showed robust expression of the antigenomic M
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segment, followed by antigenomic L and S segment, similar to what has been observed
with BUNV and UUKV57-59. When focused on viral protein-coding mRNA transcripts
(RdRp, ppM, and N), however, RVFV showed the relative RNA abundance more
consistent with the published promoter strength, L > S > M60. Both viral mRNAs (RdRp,
ppM, and N) and the antigenomes are synthesized from the same template. These
differences in expression levels of each RNA suggest that the viral polymerase, RdRp,
may exhibit different processivity on each genome segment, namely in the order of M >
L > S. It is currious that the smallest segment shows the lowest antigenome expression as
its short length is expected to be advantagoues for full-length RNA synthesis compared to
the M and L segment that are longer in length. A sequence and/or structural element
present in the M and L segment may contribute to the high processibility of RdRp during
the sysnthesis of these antigenomes.
RVFV RdRp, in addition to N, participates in viral RNA transcription and
replication. It has been sugested that RdRp can switch its function between transcriptase,
which synthesizes mRNA-length transcripts, and replicase, which synthesizes full-length
genomes and antigenomes. However, the mechanism, by which this switch in function
occurs, is unknown. The data presented in Chapter 2 may reflect the important difference
in activity of RdRp relative to the strength of promoters present in each segment, which
would be an interesting area to be explored in the future.

The effect of NSs on viral RNA synthesis
The NSs protein in RVFV is the major virulence factor that interfers with host
transcription and cellular immune response. It was hypothesized that changes in RNA
metabolism caused by NSs could affect viral RNA expression. In Chapter 2, the
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intracellular viral genomic RNA expression was quantitated in HEK293 and Vero cells
infected with two different strains of RVFV, MP-12 and rLuc. The results suggested that
the downregulation of RNA polymerase II-dependent transcription and/or retention of
host mRNA and PABP to the nucleus correlate with increased viral genomic RNA
expression.
In future studies aimed at further characterization of NSs’ effects on viral
genomic RNA expression, another RT-qPCR-based experiment can be conducted. If the
presence of NSs increases viral RNA expression, complementing rLuc by recombinant
NSs protein should increase the vRNA synthesis in RVFV infected cells. To test this,
Vero cells can be transfected with a NSs expression vector followed by infection with
rLuc. It is expected that in NSs-complemented cells, vRNA synthesis is more robust
compared to cells that overexpresses a control protein, such as GFP. Robust and balanced
expression of vRNAs is important in subsquent viral genome packaging during RVFV
infection105. Therefore, it is plausible that the virus enhances its RNA synthesis activity
through manipulation of host RNA metabolism via NSs.
NSs functions have been characterized in the context of antagonism of innate
immunity and its contribution to increasing viral titer in mammalian cells. Completion of
the proposed experiment would highlight a connection between the changes in host RNA
metabolism caused by NSs and the increased viral RNA synthesis, a novel aspect in Rift
Valley fever viral replication.

N interactions with host RNAs
The CLIP-seq experiment demonstrated that RVFV N interacts not only with
vRNAs but also with host RNAs, especially host protein-coding RNAs (Chapter 4). Upon
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RVFV infection, the expression of interferon induced genes are upregulated due to the
innate immune response. Among those, N was found interacting with transcripts that
codes for antiviral proteins, such as IFNB1, IFIT2, and OAS2. Although their expression
is upregulated at the RNA level, it is unclear if N binding to these transcripts influence
the protein level. In other viruses, N exhibits an antagonistic activity against the host
immune response. In RVFV infection, N may bind these antiviral protein-coding
transcripts to interfere with their translation, which would favor viral replication. To
understand potential antagonistic functions of RVFV N in the host immune response, the
interferon-β (IFN-β) release from N-expressing and poly(I:C)-stimulated cells could be
monitored using ELISA. Poly(I:C) is a synthetic double-stranded RNA analog that can
mimic a viral infection. If N downregulated the host interferon response by reducing IFNβ protein expression, it is expected that the N transfected cells would release less IFN-β
to the cell culture medium. Similarly, the relative protein levels for IFIT2 and OAS2 in
the presence or absence of N cound be investigated in cells expressing N and by Western
blot. If N interferes with translation of host mRNAs, the IFIT2 and OAS2 protein levels
would also be expected to decreased in N expressing cells. Although it is possible that the
N binding to mRNAs of antiviral genes was conincidental and does not affect
translatability or stability of these transcripts, it is important to investigate the protein
expression levels of these transcripts. Because N is a multifunctional protein that is an
attractive potential target for anti-RVFV therapy, potential roles for N in the
downregulation of the host immune responses should be throughly investigated.
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Viral RNA encapsidation and packaging
In Chapter 4, the interactions between vRNA and N were investigated in the
context of encapsidation and packaging efficiency. Early in infection, when the N protein
expression is low, RVFV fails to efficiently produce fully-infectious, complete viral
particles. Later in infection and concurrent with the shift in N binding from host to
vRNAs, the viruses generated exhibited higher specific infectivity.
In vivo, RVFV infects epithelial cells104 that in mammalian host, forms layers,
which is different from a typical cell culture with monolayer of adherent cells. In such
tight spacing between cells, it is expected that the virus follows the cell-to-cell spread
strategy rather than cell-free spread via liquid culture medium71. Our studies showed that
virus particles produced early in infection were largely not infectious as a single virion
since they carried sub-stoichiometric numbers of the three genomic segments. However,
the incomplete viral particles that carry one or two genomic segment(s) may be useful if
they collectively infect a neighboring cell. Therefore, it is hypothesized that collective
infection with complementing viral particles can establish a functional infection.
To test this hypothesis, the reverse genetics system106,107 can be used to generate
incomplete viral particles that carry one or two viral genomic RNAs. Creation of two and
four segmented RVFV has been described previously67,68. Vero cells can collectively be
infected with a stock of virus that carry two segments and the other stock of virus that
carry the remaining one segment. It is expected that cells infected with a mix of two
incomplete viral stocks could produce the next generation of partially and fully infectious
particles, which could be quantitated by end point titration. Completion of the proposed
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experiment would provide insight into a potential cell-to-cell spread-based strategy that is
more relavent in the host organism.
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